Ledger.Open graph →
SEC Form D · Amendment · filed August 22, 2022

Renibus Therapeutics, Inc

Offering
$25.0M
Sold
$23.4M
Exemption
Rule 506(b)
Industry
Pharmaceuticals
Location
SOUTHLAKE, TX
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (18)

Henrik J. Rasmussen · Southlake, TXDirectorJamie J. Donadio · Southlake, TXExecD. J. Keyser · Southlake, TXExec · DirectorBhupinder J. Singh · Southlake, TXExec · DirectorCarlos Guillem · Southlake, TXDirectorFrank J. Stonebanks · Southlake, TXExec · DirectorRobert K. Grunewald · Jackson, WYExec · DirectorGregory S. Leadholm · Chicago, ILExecMarshall H. Durston · Jackson, WYDirectorRyan K. Ripp · Jackson, WYExec · DirectorPete K. Fawcett · Chicago, ILDirectorAdam Edelman · Boulder, COExec · DirectorLisa Henthorne · Quebec City, Quebec, CanadaExec · DirectorRichard Hoel · Quebec City, Quebec, CanadaDirectorLouis Veronneau · Quebec City, Quebec, CanadaExec · DirectorPotrero Capital Research, LLC · SAN FRANCISCO, CAExec · DirectorRobert Holt · Bozeman, MTDirectorPeter Strom · Bozeman, MTExec

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗